Table of Contents
ISRN Oncology
Volume 2014, Article ID 931858, 7 pages
http://dx.doi.org/10.1155/2014/931858
Review Article

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia

1Department of Internal Medicine, Saint Joseph Hospital, 2900 N. Lake Shore, Chicago, IL 60657, USA
2Dow University of Health Sciences, Karachi 74200, Pakistan
3Department of Internal Medicine, Presence Resurrection Medical Center, 7435 West Talcott Avenue Chicago, IL 60631, USA

Received 19 February 2014; Accepted 12 March 2014; Published 1 April 2014

Academic Editors: L. Jia and H. Zhang

Copyright © 2014 Maliha Khan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Robak and T. Robak, “The emerging role of ibrutinb and idelalisib in the treatment of chronic lymphocytic leukemia,” Journal of Hematology & Transfusion, vol. 1, no. 1, article 1001, 2013. View at Google Scholar
  2. U. Klein, Y. Tu, G. A. Stolovitzky et al., “Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells,” Journal of Experimental Medicine, vol. 194, no. 11, pp. 1625–1638, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. American Cancer Society, Cancer Facts & Figures 2013, American Cancer Society, Atlanta, Ga, USA, 2013.
  4. I. M. Macias-Perez and I. W. Flinn, “GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia,” Current Hematologic Malignancy Reports, vol. 8, no. 1, pp. 22–27, 2013. View at Google Scholar
  5. P. Tandra, J. Krishnamurthy, V. R. Bhatt, K. Newman, J. O. Armitage, and M. Akhtari, “Autoimmune cytopenias in chronic lymphocytic leukemia, facts and myths,” Mediterranean Journal of Hematology and Infectious Diseases, vol. 5, no. 1, Article ID e2013068, 2013. View at Google Scholar
  6. L. Amrein, M. Shawi, J. Grenier, R. Aloyz, and L. Panasci, “The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro,” International Journal of Cancer, vol. 133, no. 1, pp. 247–252, 2013. View at Google Scholar
  7. E. Ten Hacken and J. Burger, “Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia-focus on the B cell receptor,” Clinical Cancer Research, 2013. View at Publisher · View at Google Scholar
  8. T. Shanafelt, “Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers,” ASH Education Program Book, vol. 2013, no. 1, pp. 158–167, 2013. View at Google Scholar
  9. C. U. Niemann, J. Jones, and A. Wiestner, “Towards targeted therapy of chronic lymphocytic leukemia.,” Advances in Experimental Medicine and Biology, vol. 792, pp. 259–291, 2013. View at Google Scholar
  10. J. A. Woyach, A. J. Johnson, and J. C. Byrd, “The B-cell receptor signaling pathway as a therapeutic target in CLL,” Blood, vol. 120, no. 6, pp. 1175–1184, 2012. View at Google Scholar
  11. I. M. Pedersen and J. C. Reed, “Microenvironmental interactions and survival of CLL B-cells,” Leukemia and Lymphoma, vol. 45, no. 12, pp. 2365–2372, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. C. U. Niemann and A. Wiestner, “B-cell receptor signaling as a driver of lymphoma development and evolution,” Seminars in Cancer Biology, vol. 23, no. 6, pp. 410–421, 2013. View at Google Scholar
  13. M. Duhren-von Minden, R. Ubelhart, D. Schneider et al., “Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling,” Nature, vol. 489, no. 7415, pp. 309–312, 2012. View at Google Scholar
  14. D. G. Efremov, A. Wiestner, and L. Laurenti, “Novel agents and emerging strategies for targeting the B-cell receptor pathway in CLL,” Mediterranean Journal of Hematology and Infectious Diseases, vol. 4, no. 1, Article ID e2012067, 2012. View at Google Scholar
  15. B. Vanhaesebroeck, J. Guillermet-Guibert, M. Graupera, and B. Bilanges, “The emerging mechanisms of isoform-specific PI3K signalling,” Nature Reviews Molecular Cell Biology, vol. 11, no. 5, pp. 329–341, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Bilancio, K. Okkenhaug, M. Camps et al., “Key role of the p110δ isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110δ function in B cells,” Blood, vol. 107, no. 2, pp. 642–650, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. S. E. M. Herman, A. L. Gordon, A. J. Wagner et al., “Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals,” Blood, vol. 116, no. 12, pp. 2078–2088, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. D. Pauls, S. T. Lafarge, I. Landego, T. Zhang, and A. J. Marshall, “The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions,” Frontiers in Immunology, vol. 3, article 224, 2012. View at Google Scholar
  19. N. Tzenaki and E. A. Papakonstanti, “p110delta PI3 kinase pathway: emerging roles in cancer,” Frontiers in Oncology, vol. 3, article 40, 2013. View at Google Scholar
  20. A. Patke, I. Mecklenbräuker, H. Erdjument-Bromage, P. Tempst, and A. Tarakhovsky, “BAFF controls B cell metabolic fitness through a PKCβ- and Akt-dependent mechanism,” Journal of Experimental Medicine, vol. 203, no. 11, pp. 2551–2562, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Henley, D. Kovesdi, and M. Turner, “B-cell responses to B-cell activation factor of the TNF family (BAFF) are impaired in the absence of PI3K delta,” European Journal of Immunology, vol. 38, no. 12, pp. 3543–3548, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Reif, K. Okkenhaug, T. Sasaki, J. M. Penninger, B. Vanhaesebroeck, and J. G. Cyster, “Cuttin edge: differential roles for phosphoinositide 3-kinases, p110γ and p110δ, lymphocyte chemotaxis and homing,” Journal of Immunology, vol. 173, no. 4, pp. 2236–2240, 2004. View at Google Scholar · View at Scopus
  23. L. So and D. A. Fruman, “PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances,” Biochemical Journal, vol. 442, no. 3, pp. 465–481, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. J. R. Arron, M. Vologodskaia, B. R. Wong et al., “A positive regulatory role for Cbl family proteins in tumor necrosis factor-related activation-induced cytokine (TRANCE) and CD40L-mediated akt activation,” Journal of Biological Chemistry, vol. 276, no. 32, pp. 30011–30017, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. T. D. Troutman, W. Hu, S. Fulenchek et al., “Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking Toll-like receptors (TLRs) to serine/threonine kinases PI3K/Akt,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 1, pp. 273–278, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Ni, A. W. MacFarlane IV, M. Toft, C. A. Lowell, K. S. Campbell, and J. A. Hamerman, “B-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 1, pp. 267–272, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Aiba, M. Kameyama, T. Yamazaki, T. F. Tedder, and T. Kurosaki, “Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase,” Blood, vol. 111, no. 3, pp. 1497–1503, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. B. J. Lannutti, S. A. Meadows, S. E. M. Herman et al., “CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability,” Blood, vol. 117, no. 2, pp. 591–594, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Ghia, N. Chiorazzi, and K. Stamatopoulos, “Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation,” Journal of Internal Medicine, vol. 264, no. 6, pp. 549–562, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Bodo, X. Zhao, A. Sharma et al., “The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways,” British Journal of Haematology, vol. 163, no. 1, pp. 72–80, 2013. View at Google Scholar
  31. H. K. Webb, H. Chen, A. S. Yu et al., “Clinical pharmacokinetics of CAL-101, a p110{delta} isoform-selective PI3K inhibitor, following single- and multiple-dose administration in healthy volunteers and patients with hematological malignancies,” ASH Annual Meeting Abstracts, vol. 116, no. 21, p. 1774, 2010. View at Google Scholar
  32. I. W. Flinn, J. C. Byrd, R. R. Furman, J. R. Brown, D. M. Benson, and S. E. Coutre, “Evidence of clinical activity in a phase 1 study of CAL-101, An Oral P110{Delta} isoform-selective inhibitor of phosphatidylinositol 3-kinase, in patients with relapsed or refractory B-cell malignancies,” ASH Annual Meeting Abstracts, vol. 114, no. 22, p. 922, 2009. View at Google Scholar
  33. J. R. Brown, R. R. Furman, I. Flinn et al., “Final results of a phase I study of idelalisib (GS-1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL,” Journal of Clinical Oncology ASCO Annual Meeting Abstracts, vol. 31, 2013, abstract 7003. View at Google Scholar
  34. M. Hallek, B. D. Cheson, D. Catovsky et al., “Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines,” Blood, vol. 111, no. 12, pp. 5446–5456, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. B. D. Cheson, J. C. Byrd, K. R. Rai et al., “Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 30, no. 23, pp. 2820–2822, 2012. View at Google Scholar
  36. S. E. Coutre, J. P. Leonard, R. R. Furman et al., “Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3Kdelta) inhibitor GS-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): results from a phase I study,” in Proceedings of the 54th ASH Annual Meeting and Exposition, 2012.
  37. J. C. Barrientos, R. R. Furman, J. Leonard et al., “Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL,” Journal of Clinical Oncology, vol. 31, 2013, abstract 7017. View at Google Scholar
  38. N. D. Wagner-Johnston, S. de Vos, S. E. Coutre et al., “Chemo-immunotherapy combination of idelalisib with bendamustine/rituximab or chlorambucil/rituximab in patients with relapsed/refractory CLL demonstrates efficacy and tolerability,” Blood, vol. 122, no. 21, p. 4176, 2013. View at Google Scholar
  39. S. D. Vos, R. R. Furman, J. C. Barrientos et al., “Idelalisib, a selective inhibitor Of PI3Kδ, in combination with bendamustine, fludarabine or chlorambucil in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL),” in Proceedings of the 55th ASH Annual Meeting and Exposition, 2013, abstract 2878.
  40. H. A. Eradat, S. E. Coutre, J. C. Barrientos et al., “A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL),” Journal of Clinical Oncology ASCO Annual Meeting Abstracts, vol. 31, 2013, abstract 7131. View at Google Scholar
  41. S. de Vos, J. P. Leonard, J. C. Barrientos et al., “A phase 1 study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with therapeutic anti-CD20 antibodies (rituximab or ofatumumab) in patients with relapsed or refractory chronic lymphocytic leukemia,” Blood, vol. 122, no. 21, p. 4180, 2013. View at Google Scholar
  42. I. Flinn, E. Kimby, F. Cotter, F. Giles, A. Janssens, and E. Pulczynski, “A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL),” in Proceedings of the ASCO Meeting Abstracts, 2013.
  43. S. M. O'Brien, N. Lamanna, T. J. Kipps et al., “A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),” Journal of Clinical OncologyASCO Annual Meeting Abstracts, vol. 31, 2013, abstract 7005.43. View at Google Scholar
  44. F. Arruga, B. Gizdic, S. Serra et al., “Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia,” Leukemia, 2013. View at Publisher · View at Google Scholar
  45. R. Karmali, L. A. Paganessi, R. R. Frank et al., “Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients,” Journal of Leukocyte Biology, vol. 93, no. 1, pp. 161–170, 2013. View at Google Scholar
  46. S. Stilgenbauer and T. Zenz, “Understanding and managing ultra high-risk chronic lymphocytic leukemia,” Hematology/American Society of Hematology. Education Program, vol. 2010, pp. 481–488, 2010. View at Google Scholar · View at Scopus
  47. S. E. Coutre, J. P. Leonard, J. C. Barrientos et al., “Clinical activity of idelalisib (GS-1101), a selective inhibitor of PI3Kd, in phase 1 and 2 trials in chronic lymphocytic leukemia (CLL): effect of del(17p)/TP53 mutation, del(11q), IGHV mutation, and NOTCH1 mutation,” ASH Annual Meeting Abstracts, vol. 1632, 2013. View at Google Scholar
  48. R. C. Prins, R. T. Burke, J. W. Tyner, B. J. Druker, M. M. Loriaux, and S. E. Spurgeon, “CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway,” Leukemia, vol. 27, no. 10, pp. 2094–2096, 2013. View at Google Scholar
  49. R. T. Burke, M. M. Loriaux, K. S. Currie et al., “A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor,” vol. 4, 2013.
  50. S. E. M. Herman, R. Lapalombella, A. L. Gordon et al., “The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia,” Blood, vol. 117, no. 16, pp. 4323–4327, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. R. R. Furman, J. P. Sharman, S. E. Coutre et al., “Idelalisib and rituximab in relapsed chronic lymphocytic leukemia,” The New England Journal of Medicine, 2014. View at Publisher · View at Google Scholar